Literature DB >> 6577912

Plasma fibronectin in myeloproliferative disorders and chronic granulocytic leukaemia.

D R Norfolk, M Bowen, B E Roberts, J A Child.   

Abstract

A significant reduction of plasma fibronectin levels was found in polycythaemia vera and myelofibrosis, the lowest levels being found in patients with marked splenomegaly. Plasma fibronectin concentration was normal in essential thrombocythaemia, and only modest reduction was seen in chronic granulocytic leukaemia in either controlled chronic phase or blast cell crisis. In a patient with myelofibrosis, the plasma fibronectin rose from less than 100 mg/l to 177 mg/l after splenectomy. Possible explanations include increased consumption of plasma fibronectin in the expanded mononuclear phagocyte system present in the liver and spleen, reduced hepatic synthesis, and the clearance of circulating immune complexes. Low plasma fibronectin concentrations may increase susceptibility to infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6577912     DOI: 10.1111/j.1365-2141.1983.tb01253.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Changes in plasma fibronectin during allogeneic bone marrow transplantation.

Authors:  D R Norfolk; M Bowen
Journal:  J Clin Pathol       Date:  1985-10       Impact factor: 3.411

2.  Composition of immune complexes and their relation to plasma fibronectin in chronic myeloproliferative disorders.

Authors:  T P Baglin; A W Simpson; S M Price; B J Boughton
Journal:  J Clin Pathol       Date:  1987-12       Impact factor: 3.411

3.  Comprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and myeloproliferative disorders.

Authors:  Prabhash Kumar Jha; Aatira Vijay; Anita Sahu; Mohammad Zahid Ashraf
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

4.  EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis.

Authors:  Alessandro Malara; Cristian Gruppi; Vittorio Abbonante; Daniele Cattaneo; Luigi De Marco; Margherita Massa; Alessandra Iurlo; Umberto Gianelli; Carlo L Balduini; Maria E Tira; Andrès F Muro; Anil K Chauhan; Vittorio Rosti; Giovanni Barosi; Alessandra Balduini
Journal:  J Exp Med       Date:  2019-02-07       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.